MOLECULAR PARTNERS AG Stock Price, News & Analysis

Molecular Partners (NASDAQ:MOLN) has appointed Martin Steegmaier, Ph.D. as Chief Scientific Officer (CSO) and member of the Executive Committee, effective October 1, 2025. Dr. Steegmaier brings extensive oncology drug development experience from his previous roles at SOTIO Biotech, MorphoSys, Roche, and Boehringer Ingelheim.

As CSO, Steegmaier will lead the research organization and advance the company's pipeline of targeted DARPin therapeutics for cancer patients, including Radio-DARPins and Switch-DARPins for logic-gated immune cell activation. His background includes significant experience in developing antibody-based therapeutics in immuno-oncology and hematology-oncology.

Molecular Partners (NASDAQ: MOLN) and Orano Med announced preclinical data for MP0726, a Radio-DARPin candidate targeting mesothelin (MSLN) for ovarian cancer treatment, at SNMMI 2025. The data showed MP0726 demonstrates high affinity and selective binding to membrane-bound MSLN, with favorable biodistribution in tumor models showing up to 34% tumor accumulation at 24 hours post-injection and a tumor-to-kidney ratio of 4.5. This represents the company's second Radio-DARPin program, with the first program MP0712 (targeting DLL3) expected to begin Phase 1 trials in H2 2025. The collaboration leverages Orano Med's expertise in targeted alpha-particle therapies with 212Pb and Molecular Partners' DARPin technology to address the challenge of shed MSLN acting as a decoy receptor in cancer treatment.

Molecular Partners (NASDAQ: MOLN) announced positive Phase 1/2a trial data for MP0533, their tetraspecific T-cell engager for relapsed/refractory acute myeloid leukemia (AML), at EHA 2025. In cohort 8, 3 out of 8 evaluable patients (>30%) achieved clinical responses after the first cycle, with one patient maintaining response beyond 6 months. The trial implemented an accelerated step-up dosing regimen, reaching target dose by day 12 instead of day 15, resulting in longer therapeutic exposure. Five out of 8 patients showed >50% blast reduction, with MP0533 demonstrating an acceptable safety profile. Based on these encouraging results, cohort 9 is now ongoing with further optimized dosing, and initial data is expected in H2 2025. Future study cohorts will evaluate MP0533 in combination with azacitidine/venetoclax.

Molecular Partners (NASDAQ: MOLN) has announced a strategic operational restructuring to enhance efficiency and extend its cash runway. The company plans to reduce its workforce by up to 40 positions (~24% of total) following a strategic review, primarily affecting research and associated functions. This restructuring will extend the company's cash reach into 2028, beyond the previous guidance of 2027. The company maintains its clinical timelines for MP0533 and MP0712, with data expected in H2 2025. CEO Patrick Amstutz emphasized that the decision aims to prioritize development of key clinical assets while ensuring future success. The company will provide affected employees with support including severance packages, job search assistance, coaching, and training opportunities. The restructuring implementation is expected to complete by end of 2025, with cost reductions becoming fully effective in early 2026.

Molecular Partners AG (NASDAQ: MOLN), a clinical-stage biotech company specializing in DARPin therapeutics, has announced its participation in two upcoming investor conferences. The management team will engage in fireside chats at: 1) The H.C. Wainwright 3rd Annual BioConnect Investor Conference at NASDAQ on May 20, 2025 at 3:30pm ET, and 2) TD Cowen's 6th Annual Oncology Innovation Summit on May 28, 2025 at 10:00am ET. Both events will be accessible via webcast through the company's website in the investors section.

Molecular Partners (NASDAQ: MOLN) reported Q1 2025 financial results and key milestones. The company maintains a strong cash position of CHF 131 million as of March 31, 2025, providing funding into 2027. Two significant developments include:

1. The expansion of their partnership with Orano Med from 4 to 10 programs for Radio-DARPin therapies, with MP0712 progressing toward IND filing and initial clinical data expected in 2025.

2. Positive progress in the MP0533 Phase 1/2a trial, with cohort 8 showing increased response rates and depth in AML treatment. The study protocol has been amended and cohort 9 enrollment has begun.

The company expects total operating expenses of CHF 55-65 million for 2025, with approximately CHF 7 million in non-cash costs.

Molecular Partners (NASDAQ: MOLN) presented three significant developments at AACR 2025:

• Positive IND-enabling data for MP0712, a Radio-DARPin targeting DLL3 for small cell lung cancer, with clinical development starting in 2025
• Initial preclinical data on a new mesothelin-targeting Radio-DARPin for solid tumors
• Preclinical proof-of-concept data for a logic-gated CD3 Switch-DARPin T cell engager

The MP0712 program showed high tumor uptake and favorable safety profiles in mouse models. The mesothelin-targeting Radio-DARPin demonstrated strong tumor accumulation while avoiding interference from shed mesothelin. The Switch-DARPin technology showed specific T cell activation in the presence of target cells and achieved tumor regression in mice without peripheral T cell activation.

Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN) held its Annual General Meeting where shareholders approved all Board proposals by a wide majority. The company, which develops DARPin therapeutics, reported a significant net loss of CHF 50.6 million for 2024, increasing the total loss carried forward to CHF 199.4 million.

Shareholders approved the annual review, financial statements, and compensation report. All Board members were re-elected for one-year terms, with William Burns re-elected as Chairman and reappointed as chair of the Nomination and Compensation Committee. KPMG AG Zurich was re-elected as statutory auditors for 2025, and Anwaltskanzlei Keller AG was chosen as independent proxy until 2026.

Molecular Partners (SIX: MOLN; NASDAQ: MOLN) has announced three poster presentations at the upcoming American Association for Cancer Research (AACR) Annual Meeting 2025, scheduled for April 25-30 in Chicago.

The presentations will showcase:

• MP0712, a Radio-DARPin targeting DLL3 labeled with 212Pb for small cell lung cancer treatment, co-developed with Orano Med, entering First-in-Human studies in 2025
• Initial preclinical data on a second 212Pb-based Radio-DARPin targeting mesothelin (MSLN) in solid tumors, also co-developed with Orano Med
• Additional preclinical proof-of-concept data on CD3 Switch-DARPin T cell engager with CD2 co-stimulation for solid tumors